✦ LIBER ✦

Long-term survival after induction therapy with idarubicin and cytosine arabinoside for de novo acute myeloid leukemia

✍ Scribed by M. Flasshove; P. Meusers; J. Schütte; R. Noppeney; D. W. Beelen; S. Sohrab; U. Roggenbuck; G. Kemmeries; G. Brittinger; S. Seeber; M. E. Scheulen

Publisher: Springer
Year: 2000
Tongue: English
Weight: 119 KB
Volume: 79
Category: Article
ISSN: 0939-5555
DOI: 10.1007/s002770000193

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

High-dose cytosine arabinoside and dauno

High-dose cytosine arabinoside and daunorubicin postremission therapy in adults with de novo acute myeloid leukemia

✍ G. Heil; P. S. Mitrou; D. Hoelzer; M. Freund; H. Link; G. Ehninger; B. Steinke; 📂 Article 📅 1995 🏛 Springer 🌐 English ⚖ 746 KB

Long-term follow-up of three randomized

Long-term follow-up of three randomized trials comparing idarubicin and daunorubicin as induction therapies for patients with untreated acute myeloid leukemia

✍ Ellin Berman; Peter Wiernik; Ralph Vogler; Enrique Vélez-Gárcia; Alfred Bartoluc 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 151 KB 👁 2 views

BACKGROUND. Most clinical trials for acute leukemia have reported results after

Comparison of toxicity and outcome in pa

Comparison of toxicity and outcome in patients with acute myeloid leukemia treated with high-dose cytosine arabinoside consolidation after induction with a regimen containing idarubicin or daunorubicin

✍ G. Seipelt; W.-K. Hofmann; H. Martin; B. Wassmann; A. Boehme; O. G. Ottmann; D. 📂 Article 📅 1998 🏛 Springer 🌐 English ⚖ 205 KB

The prognostic significance of leukemic

The prognostic significance of leukemic cells clearance kinetics evaluation during the initial course of induction therapy with HAD (homoharringtonine, cytosine arabinoside, daunorubicin) in patients with de novo acute myeloid leukemia

✍ Zhijian Xiao; Hua Xue; Rui Li; Li Zhang; Minghua Yu; Yushu Hao 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 221 KB 👁 2 views

Granulocyte colony-stimulating factor sh

Granulocyte colony-stimulating factor shortens duration of critical neutropenia and prolongs disease-free survival after sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy for refractory and relapsed acute myeloid leukemia

✍ W. Kern; C. Aul; G. Maschmeyer; R. Kuse; A. Kerkhoff; A. Grote-Metke; H. Eimerma 📂 Article 📅 1998 🏛 Springer 🌐 English ⚖ 203 KB